paragraph_ID	sentence_ID	token_ID_within_sentence	token_ID_within_document	word	lemma	byte_onset	byte_offset	POS_tag	dependency_relation	syntactic_head_ID
0	0	0	0	IPO	ipo	0	3	NOUN	compound	1
0	0	1	1	FILING	filing	4	10	NOUN	dep	75
0	0	2	2	-	-	11	12	PUNCT	punct	1
0	0	3	3	Transkaryotic	Transkaryotic	13	26	PROPN	compound	5
0	0	4	4	Therapies	Therapies	27	36	PROPN	compound	5
0	0	5	5	Inc	Inc	37	40	PROPN	appos	1
0	0	6	6	.	.	41	42	PUNCT	punct	1
1	1	0	7	WASHINGTON	WASHINGTON	43	53	PROPN	npadvmod	14
1	1	1	8	1996	1996	54	58	NUM	nummod	9
1	1	2	9	-	-	58	59	NUM	nummod	11
1	1	3	10	08	08	59	61	NUM	nummod	11
1	1	4	11	-	-	61	62	NUM	appos	7
1	1	5	12	27	27	62	64	NUM	nummod	11
2	2	0	13	Company	company	65	72	NOUN	compound	14
2	2	1	14	Name	name	73	77	NOUN	nsubj	75
2	2	2	15	Transkaryotic	Transkaryotic	78	91	PROPN	compound	17
2	2	3	16	Therapies	Therapies	92	101	PROPN	compound	17
2	2	4	17	Inc	Inc	102	105	PROPN	appos	14
3	3	0	18	Nasdaq	Nasdaq	106	112	PROPN	compound	20
3	3	1	19	Stock	Stock	113	118	PROPN	compound	20
3	3	2	20	symbol	symbol	119	125	NOUN	dobj	20
3	3	3	21	TKTX	TKTX	126	130	PROPN	appos	20
4	4	0	22	Estimated	estimate	131	140	VERB	amod	24
4	4	1	23	price	price	141	146	NOUN	compound	24
4	4	2	24	range	range	147	152	NOUN	appos	14
4	4	3	25	$	$	153	154	SYM	nmod	29
4	4	4	26	13	13	155	157	NUM	nummod	25
4	4	5	27	-	-	158	159	SYM	punct	29
4	4	6	28	$	$	160	161	SYM	quantmod	29
4	4	7	29	15	15	162	164	NUM	appos	24
4	4	8	30	/	/	165	166	PUNCT	punct	24
4	4	9	31	shr	shr	167	170	X	appos	24
5	5	0	32	Total	total	171	176	ADJ	amod	33
5	5	1	33	shares	share	177	183	NOUN	nsubj	75
5	5	2	34	to	to	184	186	PART	aux	36
5	5	3	35	be	be	187	189	AUX	auxpass	36
5	5	4	36	offered	offer	190	197	VERB	relcl	33
5	5	5	37	2.5	2.5	198	201	NUM	compound	38
5	5	6	38	million	million	202	209	NUM	dobj	36
6	6	0	39	Shrs	shr	210	214	NOUN	dep	75
6	6	1	40	offered	offer	215	222	VERB	dep	44
6	6	2	41	by	by	223	225	ADP	agent	40
6	6	3	42	company	company	226	233	NOUN	pobj	41
6	6	4	43	2.5	2.5	234	237	NUM	compound	44
6	6	5	44	million	million	238	245	NUM	appos	39
7	7	0	45	Shrs	shr	246	250	NOUN	appos	39
7	7	1	46	outstanding	outstanding	251	262	ADJ	amod	45
7	7	2	47	after	after	263	268	ADP	prep	45
7	7	3	48	ipo	ipo	269	272	NOUN	pobj	47
7	7	4	49	16,668,560	16,668,560	273	283	NUM	nummod	48
8	8	0	50	Lead	lead	284	288	NOUN	amod	51
8	8	1	51	Underwriter	underwriter	289	300	NOUN	appos	39
8	8	2	52	Morgan	Morgan	301	307	PROPN	compound	53
8	8	3	53	Stanley	Stanley	308	315	PROPN	appos	51
8	8	4	54	and	and	316	319	CCONJ	cc	53
8	8	5	55	Co	Co	320	322	PROPN	compound	56
8	8	6	56	Inc	Inc	323	326	PROPN	conj	53
9	9	0	57	Underwriters	Underwriters	327	339	PROPN	npadvmod	65
9	9	1	58	over	over	340	344	NOUN	dep	59
9	9	2	59	-	-	344	345	NOUN	dep	60
9	9	3	60	allotment	allotment	345	354	NOUN	appos	57
9	9	4	61	375,000	375,000	355	362	NUM	nummod	62
9	9	5	62	shrs	shr	363	367	NOUN	appos	60
9	9	6	63	Shares	share	368	374	NOUN	nsubjpass	66
9	9	7	64	to	to	375	377	PART	aux	66
9	9	8	65	be	be	378	380	AUX	auxpass	66
9	9	9	66	purchased	purchase	381	390	VERB	acl	39
9	9	10	67	by	by	391	393	ADP	agent	66
9	9	11	68	Hoechst	Hoechst	394	401	PROPN	compound	71
9	9	12	69	Marion	Marion	402	408	PROPN	compound	71
9	9	13	70	Roussel	Roussel	409	416	PROPN	compound	71
9	9	14	71	Inc	Inc	417	420	PROPN	pobj	67
9	9	15	72	357,143	357,143	421	428	NUM	nummod	71
9	9	16	73	Business	business	429	437	NOUN	nsubj	75
9	9	17	74	:	:	438	439	PUNCT	punct	75
9	9	18	75	developed	develop	440	449	VERB	ROOT	75
9	9	19	76	two	two	450	453	NUM	nummod	79
9	9	20	77	proprietary	proprietary	454	465	ADJ	amod	79
9	9	21	78	technology	technology	466	476	NOUN	compound	79
9	9	22	79	platforms	platform	477	486	NOUN	dobj	75
9	9	23	80	,	,	487	488	PUNCT	punct	79
9	9	24	81	gene	gene	489	493	NOUN	compound	82
9	9	25	82	activation	activation	494	504	NOUN	appos	79
9	9	26	83	and	and	505	508	CCONJ	cc	82
9	9	27	84	gene	gene	509	513	NOUN	compound	85
9	9	28	85	therapy	therapy	514	521	NOUN	conj	82
9	9	29	86	.	.	522	523	PUNCT	punct	75
10	10	0	87	Use	use	524	527	NOUN	attr	96
10	10	1	88	of	of	528	530	ADP	prep	87
10	10	2	89	Proceeds	proceed	531	539	NOUN	pobj	88
10	10	3	90	:	:	540	541	PUNCT	punct	87
10	10	4	91	Research	research	542	550	NOUN	appos	87
10	10	5	92	,	,	551	552	PUNCT	punct	91
10	10	6	93	preclinical	preclinical	553	564	ADJ	amod	97
10	10	7	94	and	and	565	568	CCONJ	cc	93
10	10	8	95	clinical	clinical	569	577	ADJ	conj	93
10	10	9	96	product	product	578	585	NOUN	compound	97
10	10	10	97	development	development	586	597	NOUN	conj	91
10	10	11	98	,	,	598	599	PUNCT	punct	97
10	10	12	99	and	and	600	603	CCONJ	cc	97
10	10	13	100	general	general	604	611	ADJ	amod	102
10	10	14	101	corporate	corporate	612	621	ADJ	amod	102
10	10	15	102	purposes	purpose	622	630	NOUN	conj	97
10	10	16	103	.	.	631	632	PUNCT	punct	87
11	11	0	104	Financial	financial	633	642	ADJ	amod	105
11	11	1	105	Data	datum	643	647	NOUN	ROOT	105
11	11	2	106	in	in	648	650	ADP	prep	105
11	11	3	107	000s	000s	651	655	NUM	pobj	106
11	11	4	108	:	:	656	657	PUNCT	punct	105
11	11	5	109	1995	1995	658	662	NUM	nummod	110
11	11	6	110	1994	1994	663	667	NUM	appos	105
12	12	0	111	-	-	668	669	NUM	punct	112
12	12	1	112	Revenue	revenue	670	677	NOUN	appos	105
12	12	2	113	$	$	678	679	SYM	nmod	114
12	12	3	114	15,400	15,400	680	686	NUM	appos	112
12	12	4	115	$	$	687	688	SYM	quantmod	116
12	12	5	116	10,000	10,000	689	695	NUM	appos	114
13	13	0	117	-	-	696	697	PUNCT	punct	119
13	13	1	118	Net	net	698	701	ADJ	amod	119
13	13	2	119	Income	income	702	708	NOUN	appos	112
13	13	3	120	(	(	709	710	PUNCT	punct	121
13	13	4	121	loss	loss	711	715	NOUN	appos	119
13	13	5	122	)	)	716	717	PUNCT	punct	121
13	13	6	123	$	$	718	719	SYM	nmod	124
13	13	7	124	2,074	2,074	720	725	NUM	appos	119
13	13	8	125	(	(	726	727	PUNCT	punct	127
13	13	9	126	$	$	728	729	SYM	nmod	127
13	13	10	127	3,422	3,422	730	735	NUM	appos	124
13	13	11	128	)	)	736	737	PUNCT	punct	119
